At the last check on Friday, AlloVir Inc.’s (NASDAQ: ALVR) stock was up $0.33, moving up 13.36 percent to $2.80. The average number of shares traded per day over the past five days has been 728,137 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.02 fall in that time frame. In the last twenty days, the average volume was 521,354, while in the previous 50 days, it was 836,498.
Since last month, ALVR stock retreated -15.41%. Shares of the company fell to $2.42 on 08/17/23, the lowest level in the past month. A 52-week high of $10.29 was reached on 02/23/23 after having rallying from a 52-week low of $2.42. Since the beginning of this year, ALVR’s stock price has dropped by -45.42% or -$2.24, and marked a new high 11 times. However, the stock has declined by -72.79% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ALVR stock investors should be aware that AlloVir Inc. (ALVR) stock had its last reported insider trading activity 29 days ago on Jul 20. Sinha Vikas disposed of 1,437 shares for $3.35 on Jul 20. It resulted in a $4,810 divestment by the insider. Hagen Brett R sold 342 shares at an average price of $3.35 on Jul 20. The insider now owns 128,828 shares following the transaction. On Jul 19, Chief Executive Officer Brainard Diana sold 8,342 shares at $3.56 apiece. The transaction was valued at $29,710.
Financial Health
In the three months ended June 29, AlloVir Inc.’s quick ratio stood at 8.50, while its current ratio was 8.50, showing that the company is able to pay off its debt. Based on annual data, ALVR earned $171.2 million in gross profit.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected AlloVir Inc. to report -$0.45 quarterly earnings, the actual figure was -$0.48 per share, beating the consensus estimate by -6.70%. During the quarter, the company generated -$47.22 million in EBITDA. The liabilities of AlloVir Inc. were 53.58 million at the end of its most recent quarter ended June 29, and its total debt was $31.5 million. The value of shareholders’ equity is $113.87 million.
Technical Picture
This quick technical analysis looks at AlloVir Inc.’s (ALVR) price momentum. With a historical volatility rate of 96.85%, the RSI 9-day stood at 48.05% on 17 August.
With respect to its five-day moving average, the current AlloVir Inc. price is down by -0.66% percent or -$0.02. At present, ALVR shares trade -18.80% below its 20-day simple moving average and -31.33% percent below its 100-day simple moving average. However, the stock is currently trading approximately -50.33% below its SMA50 and -58.29% below its SMA200.
Stochastic coefficient K was 19.33% and Stochastic coefficient D was 11.34%, while ATR was 0.23. Given the Stochastic reading of 51.17% for the 14-day period, the RSI (14) reading has been calculated as 44.83%. As of today, the MACD Oscillator reading stands at -0.17, while the 14-day reading stands at -0.25.
Analyst Ratings
BofA Securities launched its rating on AlloVir Inc. (NASDAQ: ALVR) to a Buy in a note to investors on Aug-18-23. AlloVir Inc. (ALVR) has been rated Buy by analysts. According to 0 brokerage firms, ALVR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate AlloVir Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $18.50, the current consensus forecast for the stock is $15.00 – $27.00. Based on these forecasts, analysts predict AlloVir Inc. (ALVR) will achieve an average price target of $19.75.
